Bibliography

1. Global Initiative for Asthma - Global Strategy for Asthma Management and Prevention. National Institute of Health - National Heart, Lung and Blood Institute Publication No 02-3659 Updated 2004 document.
2. Factsheet: Asthma-a worldwide problem. Document accessed on February 8, 2005 at website of International Union Against Tuberculosis and Lung Diseases (IUATLD) www.iuatld.org
3. Chowgule RV, Shetye VM, Parmar JR, Bhosale AM, Khandagale MR, Phalnitkar SV, et al. Prevalence of respiratory symptoms, bronchial hyperreactivity, and asthma in a megacity. Results of the European Community Respiratory Health Survey in Mumbai (Bombay). Am J Respir Crit Care Med 1998;158: 547-554.
4. Jindal SK, Gupta D, Aggarwal AN, Jindal RC, Singh V. Study of the prevalence of Asthma in adults in north India using a standardized field questionnaire. J Asthma 2000; 37: 345-351
5. Gupta D, Aggarwal AN, Kumar R, Jindal SK. Prevalence of bronchial Asthma and association with environmental tobacco smoke exposure in adolescent school children in Chandigarh, North India. J Asthma 2001; 38: 501-507
6. Chhabra SK, Gupta CK, Chhabra P, Rajpal S. Prevalence of bronchial asthma in school children in Delhi. J Asthma 1998; 35:291-296.
7. Singh D, Sobti PC, Arora V, Soni RK. E pidemiological study of asthma in rural children. Indian J Community Med 2002; 27:167-170
8. Awasthi S, Kalra E, Roy S, Awasthi S. Prevalence and risk factors of asthma and wheeze in school-going children in Lucknow, North India. Indian Pediatrics 2004; 41: 1205-1210.
9. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J 1998; 12: 315-335.
10. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variations in the prevalence of symptoms of asthma, allergic rhinoconjuctivits and atopic eczema: ISAAC. Lancet 1998; 351: 1225-1232.
11. Aggarwal AN, Chaudhry K, Chhabra SK, D'Souza GA, Gupta D, Jindal SK, et al. Prevalence and risk factors for bronchial asthma in Indian adults: a multicentre study. Indian J Chest Dis Allied Sci. 2005. In press
12. Gaur SN, Kumar R, Sinha R. Prevalence of bronchial asthma in petrol pump workers of Delhi. Indian J Occup Environ Med 2003; 7:13-16.
13. Mishra V. Effect of indoor air pollution from biomass combustion on prevalence of asthma in the elderly. Environ Health Perspect 2003; 111:71-78.
14. Khan S, Roy A, Christopher DJ, Cherian AM. Prevalence of bronchial asthma among bank employees of Vellore using questionnaire based data. J Indian Med Assoc 2002;100:643-644, 655.
15. Paramesh H. Epidemiology of asthma in India. Indian J Pediatr 2002; 69:309-312.
16. Chakravarthy S, Singh RB, Swaminathan S, venkatesan P. Prevalence of asthma in urban and rural children in Tamil Nadu. Natl Med J India 2002;15:260-263.
17. Pande JN, Bhatta N, Biswas D, Pandey RM, Ahluwalia G, Sidharamaiah NH, et al. Outdoor air pollution and emergency room visits at a hospital in Delhi. Indian J Chest Dis Allied Sci 2002; 44:13-19.
18. Chhabra SK, Gupta CK, Chhabra P, Rajpal S. Risk factors for development of bronchial asthma in children in Delhi. Ann Allergy Asthma Immunol 1999; 83:385-390.
19. Jindal SK, Gupta D. The relationship between tobacco smoke and bronchial asthma. Indian J Med Res 120: 2004: 443-453.
20. Jindal SK, Gupta D, Singh A. Indices of morbidity and control of asthma in patients exposed to environmental tobacco smoke. Chest 1994; 106:746-749.
21. Jindal SK, Gupta D, Chattopadhyay S, Kumar L. Environmental tobacco smoke exposure precipitates acute exacerbations in nonsmoker asthmatics. Lung India 1997; 15:168-172.
22. Reddy TS, Guleria R, Sinha S, Sharma SK, Pande JN. Domestic cooking fuel and lung functions in healthy non-smoking women. Indian J Chest Dis Allied Sci 2004; 46: 85-90.
23. Pokharel PK, Kabra SK, Kapoor SK, Pandey RM. Risk factors associated with bronchial asthma in school going children of rural Haryana. Indian J Pediatr 2001; 68:103-106.
24. Behera D, Chakrabarti T, Khanduja KL. Effect of exposure to domestic cooking fuels in bronchial asthma. Indian J Chest Dis Allied Sci 2001; 43:27-31.
25. Gupta D, Aggarwal AN, Chaudhary J, Jindal SK. Domestic fuel combustion and morbidity from asthma amongst nonsmoking women. Lung India 1999; 17:10-14.
26. Jindal SK, Jha LK, Gupta D. Bronchial hyper-responsiveness of women with asthma exposed to environmental tobacco smoke. Indian J Chest Dis Allied Sci 1999; 41:75-82.
27. Singh H, Soni RK, Gill PJS. Epidemiological and risk factors in childhood bronchial asthma. Indian J Community Med 1998; 23:42-44.
28. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-1136.
29. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144: 1202-1218.
30. Jain SK, Ramiah TJ. Spirometric studies in healthy women 15-40 years age. Indian J Chest Dis 1967; 9: 1-12.
31. Jain SK, Ramiah TJ. Normal standards of pulmonary function tests for healthy men 15-40 years old: comparison of different prediction equations (prediction formulae). Indian J Med Res 1969; 57:1453-1466.
32. Jindal SK, Wahi PL. Pulmonary function laboratory in the tropics: needs, problems and solutions. In: Lung Diseases in the Tropics (1990), Ed. O.P. Sharma, Marcel Dekker Inc., New York, pp. 523-542.
33. Udwadia FE, Sunawala JD, Sheyte VM. Lung function studies healthy Indian subjects. J Assoc Physicians India 1987; 36: 491-496.
34. Vijayan VK, Kuppurao KV, Venkatesan P, Sankaran K, Prabhakar R. Pulmonary functions in healthy young adult Indians in Madras. Thorax 1990; 45: 611-615.
35. Aggarwal AN, Gupta D, Jindal SK. Development of a simple computer programme for spirometry interpretation. J Assoc Physicians India 2002; 50: 567-570.
36. Aggarwal AN, Gupta D, Kumar V, Jindal SK. Assessment of diurnal variability of peak expiratory flow in stable asthmatics. J Asthma 2002; 39:487-91.
37. Aggarwal AN, Gupta D, Chaganti S, Jindal SK. Diurnal variation in peak expiratory flow in healthy young adults. Indian J Chest Dis Allied Sci 2002; 42:15-19.
38. Jackson H, Hubbard R. Detecting chronic obstructive pulmonary disease using peak flow rate: cross sectional survey. BMJ 2003; 327:653-54.
39. Sawyer G, Miles J, Lewis S, Fitzharris P, Pearce N, Beasley R. Classification of asthma severity: should the international guidelines be changed? Clin Exp Allergy 1998; 28: 1565-1570.
40. Thiadens HA, De Bock GH, Van Houwelingen JC, Dekker FW, De Waal MW, Springer MP, et al. Can peak expiratory flow measurements reliably identify the presence of airway obstruction and bronchodilator response as assessed by FEV1 in primary care patients presenting with a persistent cough? Thorax 1999; 54: 1055-1060.
41. Gupta D, Aggarwal AN, Subalaxmi MVS, Jindal SK. Assessing severity of asthma: Spirometric correlates with visual analogue scale (VAS). Indian J Chest Dis Allied Sci 2000; 42:95-100.
42. Newhouse MT, Dolovich MB. Control of asthma by aerosols. N Engl J Med 1986; 315: 870-874.
43. Shaw RJ, Waller JF, Hetzel MR, Clark TJ. Do oral and inhaled terbutaline have different effects on the lung? Br J Dis Chest 1982; 76: 171-176.
44. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, Smaldone GC, et al. Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines. American College of Chest Physicians/ American College of Asthma, Allergy, and Immunology. Chest 2005; 127: 335-371.
45. Cates CJ, Bara A, Crilly JA, Rowe BH. Holding chambers versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2003;(3):CD000052.
46. Bisgaard H. A metal aerosol holding chamber devised for young children with asthma. Eur Respir J 1995; 8: 856-860.
47. Brown PH, Greening AP, Crompton GK. Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitary-adrenal axis function. Thorax 1993; 48: 233-238.
48. Newman SP. A comparison of lung deposition patterns between different asthma inhalers. J Aerosol Med 1995; 8(Suppl 3): S21-S26.
49. Dolovich M. New delivery systems and propellants. Can Respir J 1999; 6: 290-295.
50. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998; 12:1346-1353.
51. Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388-392.
52. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998; 157: S1-S53.
53. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332-336.
54. Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109: 410-418.
55. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337:1405-1411.
56. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164: 1392-1397.
57. Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004; 363: 271-275.
58. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171:129-136.
59. Powell H, Gibson PG. High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children. Cochrane Database Syst Rev 2003;(4):CD004109.
60. Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, Crompton GK. Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur Respir J 1995; 8: 590-592.
61. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999; 159: 941-955.
62. Selroos O, Halme M. Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. Thorax 1991; 46: 891-894.
63. Mash B, Bheekie A, Jones PW. Inhaled versus oral steroids for adults with chronic asthma. Cochrane Database Syst Rev 2001;(1):CD002160.
64. Manser R, Reid D, Abramson M. Corticosteroids for acute severe asthma in hospitalized patients. Cochrane Database Syst Review 2001;(1):CD001740.
65. Harrison BD, Stokes TC, Hart GJ, Vaughan DA, Ali NJ, Robinson AA. Need for intravenous hydrocortisone in addition to oral prednisolone in patients admitted to hospital with severe asthma without ventilatory failure. Lancet 1986; 1:181-184.
66. O'Driscoll BR, Kalra S, Wilson M, Pickering CA, Carroll KB, Woodcock AA. Double-blind trial of steroid tapering in acute asthma. Lancet 1993; 341: 324-327.
67. Kips JC, Pauwels RA. Long-acting inhaled beta(2)-agonist therapy in asthma. Am J Respir Crit Care Med 2001; 164: 923-932.
68. Wallin A, Sandstrom T, Soderberg M, Howarth P, Lundback B, Della-Cioppa G, et al. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med 1999; 159: 79-86.
69. Li X, Ward C, Thien F, Bish R, Bamford T, Bao X, et al. An antiinflammatory effect of salmeterol, a long acting beta (2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 1999; 160: 1493-1499.
70. Nelson JA, Strauss L, Skowronski M, Ciufo R, Novak R, McFadden ER Jr. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med 1998; 339: 141-146.
71. Bleecker ER, Welch MJ, Weinstein SF, Kalberg C, Johnson M, Edwards L, et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 2000; 105: 1123-1129.
72. Johnson M. The beta-adrenoceptor. Am J Respir Crit Care Med 1998; 158: S146-S153.
73. Anderson GP, Linden A, Rabe KF. Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 1994; 7: 569-578.
74. Lemanske RF Jr, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001; 285: 2594-2603.
75. Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF Jr, Sorkness CA, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001; 285: 2583-2593.
76. Kesten S, Chapman KR, Broder I, Cartier A, Hyland RH, Knight A, et al. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am Rev Respir Dis 1991; 144: 622-625.
77. Wenzel SE, Lumry W, Manning M, Kalberg C, Cox F, Emmett A, et al. Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma. Ann Allergy Asthma Immunol 1998; 80: 463-470.
78. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320: 1368-1373.
79. Walters EH, Walters JAE, Gibson MDP. Inhaled long acting beta agonists for stable chronic asthma. Cochrane Database Syst Rev 2003; (3): CD001385.
80. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219-224.
81. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481-1488.
82. Kolbeck RC, Speir WA Jr, Carrier GO, Bransome ED Jr. Apparent irrelevance of cyclic nucleotides to the relaxation of tracheal smooth muscle induced by theophylline. Lung 1979; 156:173-183.
83. Higbee MD, Kumar M, Galant SP. Stimulation of endogenous catecholamine release by theophylline: a proposed additional mechanism of action for theophylline effects. J Allergy Clin Immunol 1982; 70:377-382.
84. Horrobin DF, Manku MS, Franks DJ, Hamet P. Methyl xanthine phosphodiesterase inhibitors behave as prostaglandin antagonists in a perfused rat mesenteric artery preparation. Prostaglandins 1977; 13:33-40.
85. Feoktistov I, Biaggioni I. Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest 1995; 96:1979-1986.
86. Nicholson CD, Shahid M. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes - their potential utility in the therapy of asthma. Pulm Pharmacol 1994; 7:1-17.
87. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, et al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 2002; 99: 8921-8926.
88. Foukas LC, Daniele N, Ktori C, Anderson KE, Jensen J, Shepherd PR. Direct effects of caffeine and theophylline on the p110d and other phosphoinositiode 3-kinases; Differential effects on lipid kinase and protein kinase activities. J Biol Chem 2002; 277: 37124-37130.
89. Ward AJ, McKenniff M, Evans JM, Page CP, Costello JF. Theophylline - an immunomodulatory role in asthma? Am Rev Respir Dis 1993; 147: 518-523.
90. Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995; 151:1907-1914.
91. Ashutosh K, Sedat M, Fragale-Jackson J. Effects of theophylline on respiratory drive in patients with chronic obstructive pulmonary disease. J Clin Pharmacol 1997; 37:1100-1107.
92. Shah L, Wilson AJ, Gibson PG, Coughlan J. Long acting beta-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Review 2003; (3): CD001281.
93. Tinkelman DG, Reed CE, Nelson HS, Offord KP. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993; 92: 64-77.
94. Reed CE, Offord KP, Nelson HS, Li JT, Tinkleman DG. Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma. The American Academy of Allergy, Asthma and Immunology Beclomethasone Dipropionate-Theophylline Study Group. J Allergy Clin Immunol 1998; 101:14-23.
95. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997;337:1412-1418.
96. Ukena D, Harnest U, Sakalauskas R, Magyar P, Vetter N, Steffen H, et al. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J 1997; 10: 2754-2760.
97. Lim S, Jatakanon A, Gordon D, Macdonald C, Chung KF, Barnes PJ. Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice. Thorax 2000; 55: 837-841.
98. Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ 2003; 326: 621-625.
99. Ng D, Salvio F, Hicks G. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Review 2004;(2):CD002314.
100. Ram FS, Cates CJ, Ducharme FM. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Review 2005; (1): CD003137.
101. Ducharme F, Schwartz Z, Hicks G, Kakuma R. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Review 2004; (2): CD003133.
102. Szefler SJ, Nelson HS. Alternative agents for antiinflammatory treatment of asthma. J Allergy Clin Immunol 1998; 102: S23-S35.
103. Wallaert B, Brun P, Ostinelli J, Murciano D, Champel F, Blaive B, et al. A comparison of two long-acting beta-agonists, oral bambuterol and inhaled salmeterol, in the treatment of moderate to severe asthmatic patients with nocturnal symptoms. The French Bambuterol Study Group. Respir Med 1999; 93: 33-38.
104. Crompton GK, Ayres JG, Basran G, Schiraldi G, Brusasco V, Eivindson A, et al. Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids. Am J Respir Crit Care Med 1999; 159: 824-828.
105. Sears MR, Taylor DR, Print CG, Lake DC, Li QQ, Flannery EM, et al. Regular inhaled beta agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-1396.
106. Taylor DR, Sears MR, Herbison GP, Flannery EM, Print CG, Lake DC, et al. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax 1993; 48: 134-138.
107. Wahedna I, Wong CS, Wisniewski AF, Pavord ID, Tattersfield AE. Asthma control during and after cessation of regular beta 2-agonist treatment. Am Rev Respir Dis 1993; 148: 707-712.
108. Drazen JM, Israel E, Boushey HA, Chinchilli VM, Fahy JV, Fish JE, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N Engl J Med 1996; 335: 841-847.
109. Dennis SM, Sharp SJ, Vickers MR, Frost CD, Crompton GK, Barnes PJ, et al. Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework. Lancet 2000; 355: 1675-1679.
110. Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, et al. The effect of polymorphisms of the beta (2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162: 75-80.
111. Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI. Asthma exacerbations during long term beta agonist use: influence of beta (2) adrenoceptor polymorphism. Thorax 2000; 55: 762-767.
112. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364: 1505-1512.
113. Milgrom H, Skoner DP, Bensch G, Kim KT, Claus R, Baumgartner RA, et al. Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol 2001; 108: 938-945.
114. Nelson HS, Bensch G, Pleskow WW, DiSantostefano R, DeGraw S, Reasner DS, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998; 102: 943-952.
115. Berger WE. Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma. Ann Allergy Asthma Immunol 2003; 90: 583-592.
116. Nowak RM, Emerman CL, Schaefer K, Disantostefano RL, Vaickus L, Roach JM. Levalbuterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study. Am J Emerg Med 2004; 22: 29-36.
117. Truitt T, Witko J, Halpern M. Levalbuterol Compared to Racemic Albuterol. Efficacy and Outcomes in Patients Hospitalized With COPD or Asthma. Chest 2003; 123: 128-135.
118. Westby M, Benson M, Gibson P. Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Review 2004; (3): CD003269.
119. Rodrigo GJ, Rodrigo C. The role of anticholinergics in acute asthma treatment. An evidence-based evaluation. Chest 2002; 121:1977-1987.
120. Plotnick LH, Ducharme FM. Combined inhaled anticholinergics and beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Review 2000; (4): CD000060.
121. Chandra P, Paliwal L, Lodha R, Kabra SK. Comparison of terbutaline and salbutamol inhalation in children with mild or moderate acute exacerbation of asthma. Indian J Pediatr 2004; 71:961-963.
122. Kumar R, Gaur SN, Vatsa HK. The role of inhaled frusemide in management of bronchial asthma. Indian J Allergy Asthma Immunol 2003;17:5-8.
123. Panigrahi L, Ghosak SK. Formulation and evaluation of pseudolatex transdermal drug delivery system of terbutaline sulphate. Indian J Pharmaceutical Sciences 2002; 64:79-82.
124. Aggarwal P, Singh O, Wali JP, Handa R, Dwivedi SN, Biswas A, Wig N. Efficacy of nebulized ipratropium in acute bronchial asthma. J Indian Acad Clin Med 2002; 3:353-359.
125. Gupta PR, Verma SK. Study on management practices of medical practitioners in bronchial asthma. Indian J Allergy Asthma Immunol 2002; 16:89-92.
126. Talib SH, Arshad M, Talib S. Efficacy of salbutamol and ipratropium bromide over salbutamol alone as inhalation drug therapy in acute bronchial asthma. Indian J Allergy Asthma Immunol 2002; 16:15-21.
127. Kumar R, Vatsa HK, Prasad G. Therapeutic response of cumulative and non-cumulative doses of inhaled salbutamol in bronchial asthma. Indian J Allergy Asthma Immunol 2001; 15:103-105.
128. Mahakalkar SM, Tibdewal S, Khobragade BP. Effect of single dose of prednisolone on hospitalization in patients of acute bronchial asthma. Indian J Med Sci 2000; 54:384-387.
129. Chhabra SK, Khanduja A, Jain D. Decreased sodium-potassium and calcium adenosine triphosphatase activity of asthma: modulation by inhaled and oral corticosteroids. Indian J Chest Dis Allied Sci 1999; 41:15-26.
130. Kumar R, Vatsa HK, Gaur SN. Comparative study of nebulized salbutamol and ipratropium bromide in acute exacerbation of bronchial asthma. Indian J Allergy Appl Immunol 1998; 12:93-95.
131. Kumar R, Vatsa HK, Gaur SN. Serial measurements of lung volumes after inhaled salbutamol and salmeterol in bronchial asthma. Indian J Allergy Appl Immunol 1998; 12:97-100.
132. Raj NS, Misra A, Guleria R, Pande JN. Theophylline clearance in undernourished asthma patients. Indian J Chest Dis Allied Sci 1998; 40:175-178.
133. Gaur SN, Agarwal G, Gupta SK. Use of LPC antagonist, choline, in the management of bronchial asthma. Indian J Chest Dis Allied Sci 1997; 39:107-113.
134. Raj NS, Guleria R, Misra A, Pande JN. Intersubject variability of serum theophylline concentration after single dose of uncoated controlled release theophylline tablet administration in asthmatic patients. Indian J Chest Dis Allied Sci 1997; 39:143-147.
135. Gupta SK, Gaur SN. A placebo controlled trial of two dosages of LPC antagonist-choline in the management of bronchial asthma. Indian J Chest Dis Allied Sci 1997; 39:149-156.
136. Thomas K, Peter JV, Cherian AM, Guyatt G. Cost effectiveness of inhaled beta-agonists vs oral salbutamol in asthma: a randomized double blind cross over study. Natl Med J India 1996; 9:159-162.
137. Chhabra SK. Beclomethasone dipropionate is effective in the control of nocturnal asthma. Lung India 1995; 13:127-131.
138. Chhabra SK. Comparison of a short course of prednisolone with sustained release theophylline in the control of nocturnal asthma. Indian J Chest Dis Allied Sci 1995; 37:7-14.
139. Gupta S, Chauhan DK, Verma A, Misra NP, Trivedi HH, Irani P, et al. Study of montelukast: a once daily leukotriene receptor antagonist in the management of chronic persistent asthma. Indian Practitioner 2003; 56:99-105.
140. Manvi FV, Dandagi PM, Gadad AP, Mastiholimath VS, Jagadeesh T. Formulation of a transdermal drug delivery system of ketotifen fumarate. Indian J Pharmaceutical Sci 2003; 65:239-243.
141. Malo JL, Cartier A, Merland N, Ghezzo H, Burek A, Morris J, et al. Four-times-a-day dosing frequency is better than a twice-a-day regimen in subjects requiring a high-dose inhaled steroid, budesonide, to control moderate to severe asthma. Am Rev Respir Dis 1989; 140: 624-628.
142. Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Review 2001; (1): CD000195.
143. Camargo Jr CA, Spooner CH, Rowe BH. Continuous versus intermittent beta-agonists for acute asthma. Cochrane Database Syst Review 2003, (4): CD001115.
144. Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Review 2001; (1): CD002178.
145. Manser R, Reid D, Abramson M. Corticosteroids for acute severe asthma in hospitalised patients. Cochrane Database Syst Review 2001; (1): CD001740.
146. Edmonds ML, Camargo Jr CA, Pollack Jr CV, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Review 2003; (3): CD002308.
147. Travers A, Jones AP, Kelly K, Barker SJ, Camargo CA, Rowe BH. Intravenous beta2-agonists for acute asthma in the emergency department. Cochrane Database Syst Review 2001; (2): CD002988.
148. Silverman RA, Osborn H, Runge J. Intravenous magnesium sulfate in the management of acute severe asthma. A multicenter randomized controlled trial. Chest 2002; 122: 489-497.
149. Jones CA, Holloway JA, Warner JO. Does atopic disease start in foetal life? Allergy 2000; 55: 2-10.
150. Bousquet J, Yssel H, Vignola AM. Is allergic asthma associated with delayed fetal maturation or the persistence of conserved fetal genes? Allergy 2000; 55: 1194-1197.
151. Kramer MS. Maternal antigen avoidance during pregnancy for preventing atopic disease in infants of women at high risk. Cochrane Database Syst Rev 2000; (4): CD000133.
152. Kaur S, Chingale SA, Kundra M. Role of breast feeding in childhood asthma. Indian J Allergy Appl Immunol1999; 13: 17-21.
153. Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N Engl J Med 1990; 323: 502-507.
154. Hesselmar B, Aberg N, Aberg B, Eriksson B, Bjorksten B. Does early exposure to cat or dog protect against later allergy development? Clin Exp Allergy 1999; 29: 611-617.
155. Platts-Mills TA, Vaughan JW, Blumenthal K, Pollart Squillace S, Sporik RB. Serum IgG and IgG4 antibodies to Fel d 1 among children exposed to 20 microg Fel d 1 at home: relevance of a nonallergic modified Th2 response. Int Arch Allergy Immunol 2001; 124: 126-129.
156. Holt PG, Macaubas C. Development of long-term tolerance versus sensitisation to environmental allergens during the perinatal period. Curr Opin Immunol 1997; 9: 782-787.
157. Warner JO. Worldwide variations in the prevalence of atopic symptoms: what does it all mean? Thorax 1999; 54 Suppl 2: S46-S51.
158. Illi S, von Mutius E, Lau S, Bergmann R, Niggemann B, Sommerfeld C, et al. Early childhood infectious diseases and the development of asthma up to school age: a birth cohort study. BMJ 2001; 322:390-395.
159. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995; 332:133-138.
160. Dezateux C, Stocks J, Dundas I, Fletcher ME. Impaired airway function and wheezing in infancy: the influence of maternal smoking and a genetic predisposition to asthma. Am J Respir Crit Care Med 1999; 159: 403-410.
161. Prasad R, Kumar R, Verma SK, Pandey US. Study of skin sensitivity to various allergens by intradermal test in patients of bronchial asthma. Indian J Allergy Asthma Immunol 2001; 15:17-21.
162. Sharma DK, Bhargava R, Ahmed Z, Pandey DK. Role of immunotherapy in nasobronchial allergies. Indian J Allergy Asthma Immunol 2003; 17:25-28.
163. Pawar SS. Sensitivity to sorghum vulgare (Jowar) pollens in allergic bronchial asthma and effect of allergen specific immunotherapy. Indian J Allergy Asthma Immunol 2002; 16:41-45.
164. Abramson M, Puy R, Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy 1999; 54:1022-1041.
165. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102: 558-562.
166. Custovic A, Simpson A, Woodcock A. Importance of indoor allergens in the induction of allergy and elicitation of allergic disease. Allergy 1998; 53: 115-20.
167. Strachan DP, Cook DG. Health effects of passive smoking and parental smoking and allergic sensitization in children. Thorax 1998; 53:117-123.
168. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002 Mar; 57: 226-230.
169. Clinical practice guidelines on bronchial asthma in adults. J Assoc Physicians India 2002; 50: 461-501.
170. Singh V, Khandelwal R, Bohra S, Gupta R, Gupta BS. Evaluation of communication skills of physicians about asthma. J Assoc Physicians India 2002; 50:1266-1269.
171. Gupta SK, Mazumdar KS, Gupta S, Mazumdar AS, Gupta S. Patient education programme in bronchial asthma in India: why, how, what and where to communicate? Indian J Chest Dis Allied Sci 1998; 40:117-124.
172. Ghosh CS, Ravindran P, Joshi M, Stearns SC. Reductions in hospital use from self management training for chronic asthmatics. Soc Sci Med 1998; 46:1087-1093.
173. Lal A, Kumar L, Malhotra S. Knowledge of asthma among parents of asthmatic children. Indian Pediatr 1995; 32:649-55.
174. Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M, Haywood P. Self management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev 2003; (1): CD001117.
175. Kaur S, Behera D, Awasthi K. Development and evaluation of self care manual for asthma. PhD Thesis. 2002 (unpublished data).
176. Bedi RS, Singh HJ. Socio-economic factors affecting inhaler therapy compliance in asthma. Lung India 1994; 12:25-26.
177. Hegde SC, Shah PB, Mahashur AA. Awareness regarding occupational asthma amongst general practitioners - a critical evaluation. Indian J Occup Environ Med 2002; 6:16-20.
178. Gupta PP, Gupta KB. Awareness about the diseases in asthma patients receiving treatment from physicians at different levels. Indian J Chest Dis Allied Sci 2001; 43: 91-95.
179. Singh K, Nain CK, Sharma BC, Jindal SK. Silent gastroesophageal reflux in patients with bronchial asthma. J Assoc Physicians India 1998; 46:179-181.
180. Talib SH, Sane SD, Gopanpallikar AM, Kumbhakarna NR. Effect of helicobacter pylori eradication therapy in patients of bronchial asthma with gastroesophageal reflex disease (GERD). J Indian Acad Clin Med 2003; 4:39-49.
181. Singh V, Wisniewski A, Britton J, Tattersfield A. Effect of yoga breathing exercises (Pranayama) on airway reactivity in subjects with asthma. Lancet 1990; 335: 1381-1383.